MedTrace Logo

Dapagliflozin DPPIV Inhibitor add-on Study

NCT00984867 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 833

Last updated 2014-06-13

Study results available
· View outcomes & findings →

Summary

This study aims to investigate how dapagliflozin can control blood sugar in patients with type 2 diabetes when added to existing treatments (sitagliptin alone or in combination with metformin). The effect of dapagliflozin on weight and blood pressure will also be studied.

Conditions

Interventions

DRUG

Dapagliflozin

10 mg tablet, oral, once daily, 48 weeks

DRUG

Placebo

Matching placebo tablet

Sponsors & Collaborators

Principal Investigators

  • Serge Jabbour, MD · Thomas Jefferson University, Philadelphia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2011-03-31
Completion
2011-09-30

Countries

  • United States
  • Argentina
  • Germany
  • Mexico
  • Poland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00984867 on ClinicalTrials.gov